Tag: options

In the first half of 2025, revenue amounted to €7,115 thousand (H1 2024: €7,809 thousand). The decline was mainly due to a more competitive pricing strategy that was implemented on the Textmagic platform. EBITDA was €2,581 thousand (H1 2024: €3,149 thousand), and the operating loss totaled to €123 thousand (H1 2024: operating profit of €1,097 thousand). Profitability was negatively affected by an increase in amortization expenses of €652 thousand, resulting from the higher volume of development activities in previous periods with the goal of improving the value proposition.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lockheed Martin To Contact Him Directly To Discuss Their Options

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Flywire Corporation (NASDAQ:FLYW), Lockheed Martin Corporation (NYSE:LMT), and Sable Offshore Corporation (NYSE:SOC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options

Increases 2025 Adjusted EBITDA Guidance